Holen Sie sich die Stockscreener-App
49.01
0.16%
-0.08
Handel nachbörslich:
48.06
-0.95
-1.94%
Schlusskurs vom Vortag:
$49.09
Offen:
$48.61
24-Stunden-Volumen:
822.24K
Relative Volume:
1.18
Marktkapitalisierung:
$3.49B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-170.73M
KGV:
-18.21
EPS:
-2.6921
Netto-Cashflow:
$-159.70M
1W Leistung:
-8.84%
1M Leistung:
-0.22%
6M Leistung:
-28.88%
1J Leistung:
+149.92%
1-Tages-Spanne:
$47.62
$49.33
1-Wochen-Bereich:
$47.62
$55.60
52-Wochen-Spanne:
$18.26
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Firmenname
Structure Therapeutics Inc Adr
Sektor
Branche
Telefon
(650) 457-1978
Adresse
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
49.01 | 3.60B | 0 | -170.73M | -159.70M | -2.6921 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-03-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-05-02 | Eingeleitet | Citigroup | Buy |
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-21 | Eingeleitet | JP Morgan | Overweight |
| 2024-04-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-07-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-25 | Fortgesetzt | Jefferies | Buy |
| 2023-02-28 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-02-28 | Eingeleitet | Guggenheim | Buy |
| 2023-02-28 | Eingeleitet | Jefferies | Buy |
| 2023-02-28 | Eingeleitet | SVB Securities | Outperform |
Alle ansehen
Structure Therapeutics Inc Adr Aktie (GPCR) Neueste Nachrichten
Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s? - TradingView
Handelsbanken Fonder AB Purchases Shares of 19,400 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics (GPCR) exec sells 3,939 ADSs under plan - Stock Titan
How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's? - TradingView
Structure Therapeutics IncADR (GPCR) News, Articles, Events & Latest Updates - Stocktwits
LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock? - TradingView
Structure Therapeutics (NASDAQ:GPCR) Rating Increased to Sell at Wall Street Zen - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge? - TradingView
LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1? - TradingView
Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock? - TradingView
Structure Therapeutics Slumps As Analysts Turn Sharply Bearish - TipRanks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Lakefront Biotherapeutics (LKFT), Prime Medicine, Inc. (PRME) and Electrocore (ECOR) - The Globe and Mail
HC Wainwright Has Bearish Forecast for GPCR Q3 Earnings - MarketBeat
Price-Driven Insight from (GPCR) for Rule-Based Strategy - Stock Traders Daily
Renaissance Technologies LLC Sells 59,400 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Lowered to Strong Sell Rating by Wall Street Zen - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Posts Quarterly Earnings Results, Misses Expectations By $0.10 EPS - MarketBeat
Piper Sandler Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
GPCR SWOT Analysis: Financial Challenges and Opportunities Revea - GuruFocus
Citizens lowers Structure Therapeutics stock price target on GLP agonist By Investing.com - Investing.com South Africa
Citigroup Cuts Structure Therapeutics (NASDAQ:GPCR) Price Target to $97.00 - MarketBeat
Structure Therapeutics (GPCR) awards options and RSUs to its CCO - Stock Titan
Structure Therapeutics Inc. (GPCR) files initial Form 3 for CCO - Stock Titan
Structure Therapeutics (NASDAQ:GPCR) Given New $110.00 Price Target at Citizens Jmp - MarketBeat
Citizens lowers Structure Therapeutics stock price target on GLP agonist - Investing.com
Structure Therapeutics Chief Commercial Officer John Joseph Berrios files initial beneficial ownership statement - Bitget
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Buy Rating Reiterated on Structure Therapeutics as Obesity Pipeline Advances; $104 Price Target Maintained - TipRanks
Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights - The Manila Times
FMR LLC discloses major 13.2% GPCR stake in Structure Therapeutics Inc (GPCR) - Stock Titan
Structure Therapeutics (GPCR) CSO sells 3,939 ADS after option exercise - Stock Titan
Structure Therapeutics Inc. (GPCR) Stock Analysis: Potential Upside of 116.78% Amid Promising Clinical Trials - DirectorsTalk Interviews
Avidity Partners Management LP Buys Shares of 30,000 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Upgraded at Wall Street Zen - MarketBeat
Janus Henderson Group PLC Purchases 264,833 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics (GPCR) Projected to Release Quarterly Earnings on Thursday - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), Atea Pharmaceuticals (AVIR) - The Globe and Mail
Wall Street Analysts Are Neutral on Top Healthcare Picks - The Globe and Mail
Rock Springs Capital Management LP Sells 108,019 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Bought by Orbimed Advisors LLC - MarketBeat
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Atricure (ATRC) - The Globe and Mail
GPCR|Structure Therapeutics Inc|Price:49.000| - TradingKey
Form 4 Structure Therapeutics Inc ADR For: 24 July By Investing.com - Investing.com South Africa
A small-cap contender looking to challenge the weight-loss drug giants | 2026-07-24 | Investing News - Stockhouse
FMR LLC Discloses Major Beneficial Ownership Changes in Structure Therapeutics Inc. - Kalkine Media
FMR LLC funds sell 17,452 Structure Therapeutics (GPCR) ADS at $50.07 - Stock Titan
PSquared Asset Management AG Buys Shares of 35,000 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
GPCR: Structure Therapeutics IncADR Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q2 Results? - TradingView
Structure Therapeutics Inc. Sponsored ADR $GPCR Stake Lessened by Monashee Investment Management LLC - MarketBeat
Finanzdaten der Structure Therapeutics Inc Adr-Aktie (GPCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):